Literature DB >> 20705373

N-3 polyunsaturated fatty acids early supplementation improves ultrasound indices of endothelial function, but not through NO inhibitors in patients with acute myocardial infarction: N-3 PUFA supplementation in acute myocardial infarction.

Maciej Haberka1, Katarzyna Mizia-Stec, Magdalena Mizia, Joanna Janowska, Klaudia Gieszczyk, Artur Chmiel, Barbara Zahorska-Markiewicz, Zbigniew Gąsior.   

Abstract

BACKGROUND & AIMS: Our aim was to evaluate early initiated one month n-3 polyunsaturated fatty acids (PUFA) supplementation effects on ultrasound indices of endothelial function and serum asymmetric dimethylarginine (ADMA) levels in patients with acute myocardial infarction (AMI).
METHODS: Forty patients with AMI and successful percutaneous coronary intervention (PCI) were recruited into the study and randomized to the study group (group P; n = 20; standard therapy + n-3 PUFA 1 g daily) or the control group (group C; n = 20; standard therapy). Ultrasound indices of endothelial function: flow-mediated dilatation (FMD), nitroglycerin-mediated dilatation (NMD) and serum ADMA concentrations (ELISA) were obtained before and after one month (30 ± 1 days) therapy (presented as means ± standard deviations).
RESULTS: There was a significant difference between both groups in mean delta (baseline/after one month) FMD (P: 8.1 ± 12.6% vs C: -2.2 ± 11.8%; p = 0.02) with no difference in mean delta NMD (P: 3.3 ± 11.9% vs 0.66 ± 14.3%; p = 0.53). We found also a significant increase in mean FMD (7.4 ± 6.4 to 15.5 ± 10.5%; p = 0.02) with a nonsignificant change in mean NMD values (26.9 ± 12.1 to 30.2 ± 14.0%; p = 0.24) after 1-month therapy with n-3 PUFA. FMD and NMD mean values did not change in control patients (FMD: 11.6 ± 6.1% to 9.4 ± 8.0%; p = 0.5 NMD: 25.1 ± 11.4% to 25.8 ± 14.0%; p = 0.84). The comparison of mean delta ADMA values for both groups revealed no differences (P: 6.2 ± 9.7 μmol/l vs C: 3.6 ± 9.5 μmol/l; p = 0.43). Mean serum ADMA concentrations were significantly increased after 1-month therapy in the group P (P: 2.1 ± 1.8 to 8.3 ± 9.7 μmol/l; p = 0.001; C: 4.5 ± 7.1 to 8.1 ± 9.5 μmol/l; p = 0.09). However, there was a nonsignificant difference in mean baseline serum ADMA levels between both groups (P: 2.1 ± 1.8 μmol/l vs C: 4.5 ± 7.1 μmol/l; p = 0.32). There were no significant correlations between FMD, NMD, ADMA levels and demographic, clinical or biochemical parameters.
CONCLUSIONS: Early and short-term n-3 PUFA supplementation improved ultrasound indices of endothelial function without affecting serum ADMA levels in patients with AMI and successful primary PCI.
Copyright © 2010 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20705373     DOI: 10.1016/j.clnu.2010.07.011

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  11 in total

1.  Association of two polymorphisms in the FADS1/FADS2 gene cluster and the risk of coronary artery disease and ischemic stroke.

Authors:  Qian Yang; Rui-Xing Yin; Xiao-Li Cao; Dong-Feng Wu; Wu-Xian Chen; Yi-Jiang Zhou
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

Review 2.  Clinical Advances in Immunonutrition and Atherosclerosis: A Review.

Authors:  Ana María Ruiz-León; María Lapuente; Ramon Estruch; Rosa Casas
Journal:  Front Immunol       Date:  2019-04-24       Impact factor: 7.561

3.  Effect of fish oil supplementation on fasting vascular endothelial function in humans: a meta-analysis of randomized controlled trials.

Authors:  Wei Xin; Wei Wei; Xiaoying Li
Journal:  PLoS One       Date:  2012-09-21       Impact factor: 3.240

4.  Effect of ω-3 fatty acid supplementation on endothelial function, endogenous fibrinolysis and platelet activation in patients with a previous myocardial infarction: a randomised controlled trial.

Authors:  Jehangir N Din; Jaydeep Sarma; Scott A Harding; Karin Lyall; David E Newby; Andrew D Flapan
Journal:  BMJ Open       Date:  2013-09-25       Impact factor: 2.692

5.  Randomization to Omega-3 Fatty Acid Supplementation and Endothelial Function in COPD: The COD-Fish Randomized Controlled Trial.

Authors:  John S Kim; Michael A Thomashow; Natalie H Yip; Kristin M Burkart; Christian M Lo Cascio; Daichi Shimbo; R Graham Barr
Journal:  Chronic Obstr Pulm Dis       Date:  2021-01

Review 6.  Omega-3 Polyunsaturated Fatty Acids: Structural and Functional Effects on the Vascular Wall.

Authors:  Michela Zanetti; Andrea Grillo; Pasquale Losurdo; Emiliano Panizon; Filippo Mearelli; Luigi Cattin; Rocco Barazzoni; Renzo Carretta
Journal:  Biomed Res Int       Date:  2015-08-02       Impact factor: 3.411

Review 7.  Atherosclerosis, dyslipidemia, and inflammation: the significant role of polyunsaturated Fatty acids.

Authors:  Mariarita Dessì; Annalisa Noce; Pierfrancesco Bertucci; Simone Manca di Villahermosa; Rossella Zenobi; Veronica Castagnola; Eliana Addessi; Nicola Di Daniele
Journal:  ISRN Inflamm       Date:  2013-05-12

8.  Docosahexaenoic acid supplementation, vascular function and risk factors for cardiovascular disease: a randomized controlled trial in young adults.

Authors:  Atul Singhal; Julie Lanigan; Clare Storry; Sarah Low; Toni Birbara; Alan Lucas; John Deanfield
Journal:  J Am Heart Assoc       Date:  2013-07-01       Impact factor: 5.501

9.  Importance of extracellular matrix and growth state for the EA.hy926 endothelial cell response to polyunsaturated fatty acids.

Authors:  Youjia Du; Carla G Taylor; Harold M Aukema; Peter Zahradka
Journal:  PLoS One       Date:  2018-05-15       Impact factor: 3.240

Review 10.  Dietary and Pharmacological Fatty Acids and Cardiovascular Health.

Authors:  Huaizhu Wu; Lu Xu; Christie M Ballantyne
Journal:  J Clin Endocrinol Metab       Date:  2020-04-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.